

VAPOTHERM SECURES \$20.5 MILLION IN NEW EQUITY FINANCING



Vapotherm, the global leader in developing High Flow Therapy products for the respiratory industry, has secured \$20.5 million in new equity financing. The financing was led by GE Asset Management (on behalf of the General Electric Pension Trust), with participation by Cross Creek Capital (a Wasatch Advisors company) and Integral Capital Partners; all three are new investors in Vapotherm. Existing investors of Vapotherm, QuestMark Partners and Kaiser Permanente Ventures, also participated in the round. "We are extremely pleased to have the support of our new and existing investors. The caliber of the investor syndicate is recognition of the progress made by the Company's management and employees, and indicative of the significant opportunity ahead for a wide range of products based on the Company's platform technology," noted Vapotherm's President & CEO, Robert Storey.

Vapotherm products are currently used in neonatal, pediatric and adult applications in hundreds of hospital locations throughout the US and in more than 20 countries worldwide. The financing will support the Company's growth plans including new product development, sales expansion and the launch of Vapotherm's newest acute care device, Precision Flow™, which recently earned 510(k) clearance from the Food and Drug Administration.

"We are very glad to be involved with Vapotherm, not only at this critical milestone with the US launch of Precision Flow™, but as the Company continues its leadership role in High Flow Therapy and develops additional respiratory devices for large and unmet clinical needs," said David Stewart, Managing Director (Private Equity) of GE Asset Management. Brian Stansky, Managing Director of Integral Capital Partners, stated, "We are excited about the broad application potential for Vapotherm's High Flow Therapy system to create multiple franchises in the treatment of respiratory conditions, sleep apnea, and drug delivery." "We believe their long term growth prospects are very promising, and we look forward to the introduction of additional breakthrough products in their pipeline," added Karey Barker, Managing Director of Cross Creek Capital, a private equity affiliate of Wasatch Advisors.

HYBRID BABY TAPE™ AND HYBRID PEDIATRIC TAPE™ PROVIDING THE RIGHT TAPE FOR THE RIGHT HOLD™



B&B Medical Technologies has released The Hybrid Tape™ collection for use in all Neonatal and Pediatric care environments. Hybrid Baby Tape™ and Hybrid Pediatric Tape™ are a unique combination of tapes that combine the gentle qualities of hydrocolloid to safely adhere to tender skin with a specially formulated acrylic adhesive strip to tightly secure endotracheal tubes, NG/OG tubes, cannulas and small catheters. Latex-free and hypoallergenic, Hybrid Baby Tape™ and Hybrid Pediatric Tape™ dramatically improve the functionality, comfort and reliability of securing devices for infants and pediatric patients while improving quality of patient care, Providing the Right Tape for the Right HoldSM.

Hybrid Baby Tape™ and Hybrid Pediatric Tape™ are pre-cut tapes are specially designed to that save the clinician time and enable one-person application. Hybrid Tapes are flexible yet provide firm adhesion while also absorbing exudates. The skin friendly hydrocolloid tape can easily be removed with water without damaging the skin. The tape may be trimmed to fit individual facial contours. Hybrid Baby Tape™ and Hybrid Pediatric Tape™ are for use in the NICU, PICU, Labor & Delivery, OR, Emergency Department and transport environments to secure artificial airways and other vital tubes and catheters. The tapes are packaged as a complete kit with two each Hybrid Tapes, two each skin preps and additional hydrocolloid strips for securing NG/OG tubes, small catheters and cannulas.

CLINICAL FOUNDATION'S EDUCATION PROGRAM REACHES AN IMPORTANT MILESTONE

Clinical Foundations, an AARC accredited continuing education program dedicated to helping respiratory therapists stay current on clinical trends, has reached an important milestone. As of July 2008, well over 10,000 respiratory therapists have successfully participated in this self-study program and have earned valuable CRCEs, making this program a successful educational initiative.

As our aging population grows, so does the prevalence of respiratory-related diseases. To meet this medical need, a variety of new respiratory diagnostic and treatment options are being developed. With the availability of these new options, respiratory care professionals will require the most up-to-date, scientifically- and clinically-based information to help them make informed decisions to maximize patient outcomes - this is the goal of Clinical Foundations.

nSPIRE HEALTH APPOINTS DR. ROBERT CRAPO AS CHAIRMAN OF SCIENTIFIC & MEDICAL ADVISORY BOARD



nSpire Health announced the recent appointment of Dr. Robert Crapo as chairman of its scientific and medical advisory board. Dr. Crapo has served on the National Heart and Lung's Asthma Clinical Research Network Protocol Review Committee, has been a member of the American Thoracic Society Committee on proficiency standards for clinical pulmonary laboratories since 1983 until recently, and chaired the committee since 1993. He is medical director of the pulmonary laboratory at LDS Hospital in Salt Lake City, and the recipient of the 2006 distinguished scientist award from the American College of Chest Physicians. Under Dr. Crapo's chairmanship, the nSpire Health advisory board supports the company's Strategic and Product Planning efforts providing a direct link between the company, clinicians, scientists, and other key opinion leaders in the cardio-pulmonary marketplace. Members of the board assist in developing the vision for products and services and evaluate the company's emerging technologies. Board members directly develop clinical trial protocols for the world's most prominent pharmaceutical companies and contribute to the company's worldwide educational efforts.

"Dr. Crapo is an expert in the diagnosis and treatment of lung disease", stated Michael Sims, President and CEO of nSpire Health. "His investigative research and numerous publications have defined normal values for pulmonary function testing and guidelines for pulmonary labs used around the world. Dr. Crapo's experience in clinical trials research and his ability to assemble a world-class team of scientists and physicians will significantly contribute to our vision of revolutionizing the way the world detects and treats respiratory diseases." "I'm pleased to support nSpire Health's vision for the future of cardiopulmonary healthcare and chair the scientific and medical advisory board", Dr. Crapo said. "It is a valuable opportunity to bring together clinicians, patients, and industry in a partnership resulting in enhanced patient care."

MASIMO ANNOUNCES DESATURATION INDEX 3D ALARM AS STANDARD FEATURE IN ALL RADICAL-7 PULSE CO-OX DEVICES



Masimo, the inventor of Pulse CO-Oximetry and Measure-Through-Motion-and-Low-Perfusion pulse oximetry, announced that all customers purchasing the Masimo Radical-7, the company's flagship product, will now receive Desat Index 3D Alarm as a standard feature. Conventional pulse oximeters typically alarm based on large/isolated drops in O2 saturation values, known as a "desaturation". However, published research shows that a cycle of moderate desaturations has been shown to precede respiratory failure in hospitalized patients. Masimo Desat Index 3D Alarm enables advanced notification of these conditions, based on clinician-specified severity and number of desaturations occurring in a specified period of time.

Michael O'Reilly, MD, Masimo Executive Vice President of Medical Affairs, stated; "When combined with the proven ability of Masimo Signal Extraction Technology (SET) to dramatically reduce false desaturation alarms and improve the detection of true desaturations, Masimo Desat Index 3D Alarm advances patient care by allowing earlier intervention to prevent adverse respiratory events." Joe Kiani, Chairman and CEO of Masimo, stated; "Masimo has been selling Desat Index 3D Alarm as an option for almost three years. In light of our soon-to-be released breakthrough innovation, noninvasive and continuous hemoglobin monitoring technology, we are pleased to now offer Desat Index 3D Alarm as a standard feature."

MAQUET ANNOUNCES NEW CONTRACT WITH HEALTHTRUST



Maquet, Inc. has been awarded a 3 year ventilator contract with HealthTrust Purchasing Group (HealthTrust), effective August 2008. Jennie Haag, ventilation product manager for MAQUET commented, "This is an excellent opportunity for MAQUET. We are very excited that our SERVO ventilation platform will now be available to HealthTrust members, and we look forward to developing partnerships with its member hospitals." MAQUET Critical Care is the global leader in ICU ventilators. The SERVO-i ventilator is known for its ease of use, upgradeability and innovative operating modes with well over 100,000 units in hospitals worldwide. MAQUET's commitment to ventilation research and development positions SERVO as the number one ventilator worldwide.

HealthTrust Purchasing Group, headquartered in Brentwood, Tennessee, is a group purchasing organization that supports over 1400 not-for-profit and for-profit acute care facilities, plus ambulatory surgery centers, physician practices, and alternate care sites. With an annual purchasing volume by its members of more than \$13 billion, HealthTrust is committed to obtaining the best price for clinically-recommended products, ensuring their timely delivery and continuously evaluating and improving its services to the patients, physicians and clinicians it serves.